The Couvet factory in western Switzerland employs 100 staff manufacturing medicines in capsule and tablet form. It is expected to pass into WuXi’s hands for an undisclosed sum following regulatory approval in the second quarter of this year. Couvet will be the first European drugs production site for the Chinese firm, which acquired the company to boost its global imprint.
There is no indication at this stage whether the change of ownership will affect jobs at the production facility.
Bristol Myers Squibb currently employs around 1,220 people at five locations in Switzerland, including Couvet. The company said it was committed to staying in Switzerland despite the WuXi deal.
“This is an important step in the ongoing evolution of our manufacturing network to support our product portfolio,” stated Bristol Myers Squibb senior executive Lou SchmuklerExternal link. “Switzerland remains an important strategic location for Bristol Myers Squibb, and we look forward to maintaining a strong presence in the Neuchâtel area.”
Switzerland abstains from vote on Palestinian bid for full UN membership
This content was published on
On Friday, Switzerland abstained from the vote at the General Assembly on granting the Palestinians new rights at the United Nations (UN).
Protein in abdominal fat could help shape obesity treatment
This content was published on
The study analysed fat cells from different locations in the body, and found that those in the abdomen have unique properties.
North African asylum claims fall after rapid Swiss processing
This content was published on
The accelerated procedure, now out of its test phase, has resulted in a significant drop in applications from North African countries.
This content was published on
The artist's song "The Code" focuses on their journey as a nonbinary individual. It is one of the favourites to win this year's contest.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Swiss logistics firm to distribute Moderna Covid vaccine globally
This content was published on
Swiss company Kühne+Nagel has concluded a distribution and storage agreement for the Covid-19 vaccine developed by the American biotech firm.
Pandemic leads to historic drop in Swiss foreign trade
This content was published on
Exports and imports declined by CHF40 billion ($45 billion) in 2020 due to the Covid-19 pandemic, setting foreign trade levels back by three years.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.